AKT1 and hepatocellular carcinoma: More importantly, either HDACi or AKTi could sensitize these HCC cells to Lenvatinib, the combination of Lenvatinib with SAHA or AZD5363 targets the AKT signaling pathway could overcome Lenvatinib resistance.